Literature DB >> 12065723

Reconsideration of 5-hydroxytryptamine (5-HT)(7) receptor distribution using [(3)H]5-carboxamidotryptamine and [(3)H]8-hydroxy-2-(di-n-propylamino)tetraline: analysis in brain of 5-HT(1A) knockout and 5-HT(1A/1B) double-knockout mice.

Pascal Bonaventure1, Diane Nepomuceno, Annette Kwok, Wenying Chai, Xavier Langlois, Rene Hen, Kimberly Stark, Nicholas Carruthers, Timothy W Lovenberg.   

Abstract

The characterization and anatomical distribution of 5-hydroxytryptamine (5-HT)(7) receptor binding sites in brain tissue has been hampered by the lack of a specific radioligand. In the present autoradiographic study, we took advantage of 5-HT(1A) knockout and 5-HT(1A/1B) double-knockout mice to revisit the pharmacological characterization and anatomical localization of 5-HT(7) binding sites in mouse brain using [(3)H]5-carboxamidotryptamine (5-CT) and [(3)H]8-hydroxy-2-(di-n-propylamino)tetraline (8-OH-DPAT). The distribution pattern of [(3)H]5-CT binding sites (2 nM) in the brain of mice lacking the 5-HT(1A/1B) receptor was scarce and confined to the septum, globus pallidus, thalamus, hypothalamus, amygdala, cortex, and substantia nigra. The low densities of [(3)H]5-CT binding sites detected in septum, thalamus, hypothalamus, amygdala, and cortex were displaced by 10 microM of the selective 5-HT(7) receptor antagonist (R)-3-(2-(2-(4-methylpiperidin-1-yl) ethyl)pyrrolidine-1-sulfonyl) phenol (SB-269970). The SB-269970-insensitive [(3)H]5-CT binding sites detected in globus pallidus and substantia nigra of 5-HT(1A/1B) knockout mice were displaced by N-[3-(2-dimethylamino)ethoxy-4-methoxy-phenyl]-2'-methyl-4'- (5-methyl-1,2,4-oxadiazol-3-yl)-(1,1'-biphenyl)-4-carboxamide hydrochloride (SB-216641) (1 microM), demonstrating the 5-HT(1D) nature of these binding sites. In contrast to the low densities of [(3)H]5-CT binding sites, high-to-moderate densities of [(3)H]8-OH-DPAT binding sites (10 nM) were found throughout the brain of 5-HT(1A) and 5-HT(1A/1B) knockout mice (olfactory system, septum, thalamus, hypothalamus, amygdala, CA3 field of the hippocampus, cortical mantle, and central gray). These [(3)H]8-OH-DPAT binding sites were displaced by 10 microM SB-269970, risperidone, and methiothepin but not by pindolol, N-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide (WAY- 100135), or citalopram. We conclude that despite its high affinity for the 5-HT(7) receptor in tissue homogenates, [(3)H]5-CT is not a good tracer for measuring 5-HT(7) receptor binding sites autoradiographically. Also, the lower affinity ligand [(3)H]8-OH-DPAT is a much better tracer for autoradiographic studies at the 5-HT(7) receptor binding sites.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065723     DOI: 10.1124/jpet.302.1.240

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

Review 1.  Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.

Authors:  Marcello Leopoldo; Enza Lacivita; Francesco Berardi; Roberto Perrone; Peter B Hedlund
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

2.  [(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand.

Authors:  Peter Heusler; Christiane Palmier; Stéphanie Tardif; Sophie Bernois; Francis C Colpaert; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-08-27       Impact factor: 3.000

3.  Modulation of 5-HT7 receptor: effect on object recognition performances in mice.

Authors:  Thomas Freret; Eleni Paizanis; Gregory Beaudet; Andreia Gusmao-Montaigne; Gerald Nee; François Dauphin; Valentine Bouet; Michel Boulouard
Journal:  Psychopharmacology (Berl)       Date:  2013-08-31       Impact factor: 4.530

Review 4.  Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives.

Authors:  Anne Matthys; Guy Haegeman; Kathleen Van Craenenbroeck; Peter Vanhoenacker
Journal:  Mol Neurobiol       Date:  2011-03-22       Impact factor: 5.590

Review 5.  The 5-HT(7) receptor in learning and memory.

Authors:  Amanda J Roberts; Peter B Hedlund
Journal:  Hippocampus       Date:  2011-04-11       Impact factor: 3.899

6.  Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation.

Authors:  Baoman Li; Shiquen Zhang; Min Li; Leif Hertz; Liang Peng
Journal:  Psychopharmacology (Berl)       Date:  2009-08-07       Impact factor: 4.530

7.  Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species.

Authors:  Francisco J Martín-Cora; Angel Pazos
Journal:  Br J Pharmacol       Date:  2003-12-01       Impact factor: 8.739

8.  Effects of geissoschizine methyl ether, an indole alkaloid in Uncaria hook, a constituent of yokukansan, on human recombinant serotonin 7 receptor.

Authors:  Toshiyuki Ueki; Akinori Nishi; Sachiko Imamura; Hitomi Kanno; Kazushige Mizoguchi; Kyoji Sekiguchi; Yasushi Ikarashi; Yoshio Kase
Journal:  Cell Mol Neurobiol       Date:  2012-09-12       Impact factor: 5.046

9.  A 5-HT7 heteroreceptor-mediated inhibition of [3H]serotonin release in raphe nuclei slices of the rat: evidence for a serotonergic-glutamatergic interaction.

Authors:  Laszlo G Harsing; Ibolya Prauda; Jozsef Barkoczy; Peter Matyus; Zsolt Juranyi
Journal:  Neurochem Res       Date:  2004-08       Impact factor: 3.996

10.  Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist.

Authors:  A J Barbier; C Berridge; C Dugovic; A D Laposky; S J Wilson; J Boggs; L Aluisio; B Lord; C Mazur; C M Pudiak; X Langlois; W Xiao; R Apodaca; N I Carruthers; T W Lovenberg
Journal:  Br J Pharmacol       Date:  2004-10-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.